This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Edward Cowen, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00971620
First received: September 3, 2009
Last updated: February 23, 2017
Last verified: February 2017
  Purpose

Cutaneous leiomyomas are benign tumors of smooth muscle origin. They can be very painful, and current treatments for the tumors and for the associated pain do not produce satisfactory results. One potential treatment for localized severe muscle pain involves injections with botulinum toxin A. This study will investigate the effectiveness, side effects, and dosage of botulinum toxin A (BOTOX) as a treatment for patients with pain associated with cutaneous leiomyomas.

This study will include 18 subjects, all of whom will be 18 years of age and older, who have pain associated with cutaneous leiomyomas.

For the 24-week study, patients will be randomly assigned to one of two treatment groups. Neither the study team nor the patient will know to which group patients have been assigned. Before the study begins, all participants must provide a full medical history for research and evaluation purposes, fill out pain and quality-of-life questionnaires, and undergo an ice test in which researchers will apply ice to the site of the cutaneous leiomyomas and ask participants to evaluate the level of pain before and after ice application. Both groups will be required to keep a pain diary throughout the study to record their level of pain on a daily basis, and will be asked to avoid or restrict the use of specific medications or other remedies to treat the pain.

At the first visit (Week 0), one group will receive a prescribed dose of botulinum toxin A, which will be administered as an injection into the leiomyoma, and the other (control) group will receive a placebo injection of a saline solution. Patients will return 4 weeks later, at which time they will undergo a medical examination, and the ice test, and complete questionnaires to assess responses and level of pain. Patients will return in Week 12, at which time the group assignment will be revealed (un-blinded) to investigators and patients. Patients who received placebo injections will be offered the opportunity to receive injection of botulinum toxin A into their leiomyomas. All patients will undergo a medical examination, the ice test, complete questionnaires, and continue completing their daily pain diaries at home. The final visit, in Week 24, will follow the same procedure as the Week 4 visit.

At the end of the study, patients may be eligible to have one or more of the painful cutaneous leiomyomas surgically removed if the researchers believe that the skin lesions can be removed with a reasonable cosmetic result.


Condition Intervention Phase
Cutaneous Leiomyomas Hereditary Leiomyomatosis and Renal Cell Cancer Biological: Botulinum toxin type A Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

Resource links provided by NLM:


Further study details as provided by Edward Cowen, M.D., National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory [ Time Frame: Between week 0 and week 4 ]
    Change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls. The BPI uses an arbitrary units on a 0-10 scale. For the purposes of the statistical calculation, a difference of 1 standard deviation between groups at baseline vs. week 4 was considered significant. Any BPI value above zero (no pain) is abnormal. The mean change indicates mean change in pain score.

  • Median Change in Average Pain Between Two Arms [ Time Frame: Between weeks 0 and week 4 ]
    Change in average pain was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)).


Secondary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: 37 months ]
    Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.

  • Visual Analog Scale (VAS) of Patient Perceived Pain at Leiomyoma Site Prior to Ice Provocation at Week 0 vs. Week 4 [ Time Frame: Week 0 vs. week 4 ]
    The VAS is a commonly used validated tool for assessment of pain. For this measure, a 10-cm VAS was used to assess current patient pain/discomfort before application of ice to study lesions at week 0 and week 4. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Range is 0-10; 0 is no pain and 10 is worst possible pain.

  • Comparison of Change in Skin Related Quality of Life by Total Dermatology Life Quality Index (DLQI) at Week 0 vs. Week 4 [ Time Frame: Week 0 vs. week 4 ]
    The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Score is 0-30 based on 10 questions. The higher the score, the more quality of life is impaired.

  • Specific Skin Pain-Related Question on the Dermatology Life Quality Index [ Time Frame: Week 0 vs. week 4 ]
    The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Participants response to the question "Over the last week, how itchy, sore, painful or stinging has your skin been?" was assessed by the Dermatology Life Quality Index. This outcome refers to a single specific question on the DLQI, so the range for this outcome is 0-3. Lower values in the DLQI indicate less impairment (or greater improvement) in life quality from the skin disease.

  • Change in Post-Ice Provocation Visual Analog Score (VAS) Between Week 12 and Week 24 [ Time Frame: Between week 12 and 24 ]
    The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 denotes worse pain than 0.

  • Immunohistochemical Staining of Cutaneous Leiomyomas for Acetylcholinesterase (AchE) Before (i.e.,Week 0) and 12 Weeks After Botulinum Toxin Administration [ Time Frame: Week 0 vs. week 12 ]
    AchE staining was scored as 0 (none), 1 (rare), 2 (scattered), or 3 (focal or greater).

  • Immunohistochemical Staining of Cutaneous Leiomyomas for C-fos Before (i.e., Week 0) and 12 Weeks After Botulinum Toxin Administration [ Time Frame: Week 0 vs. week 12 ]
    c-fos, a marker of neuronal activation after pain stimulation, was scored as 0 (none), 1 (scattered), 2 (<66% of tumor cells), or 3 (≥66% of tumor cells).

  • Percentage of Patients With a Change in Average Pain Score [ Time Frame: Week 0 score vs. week 4 score ]
    Average pain was determined from a 0-10 scale question on the Brief Pain Inventory (BPI). 10 denotes worse pain.

  • Percentage of Patients With a Change in Pre-Ice Visual Analog Score (VAS) Between Week 0 and Week 4 [ Time Frame: Week 0 vs. week 4 ]
    The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale of 0-10. 10 = worse pain.

  • Percentage of Patients With a Change in Post-Ice Visual Analog Score (VAS) Between Week 0 and Week 4 [ Time Frame: Week 0 vs. week 4 ]
    The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 = worse pain.

  • Worst Pain Severity [ Time Frame: Week 0 vs. week 4 ]
    Pain severity was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)). This outcome was based on a single 0-10 question on the BPI.


Enrollment: 18
Actual Study Start Date: November 17, 2008
Study Completion Date: October 12, 2016
Primary Completion Date: January 9, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BTX-A
BTX-A intralesional injection
Biological: Botulinum toxin type A
Given as an intralesional injection.
Other Name: BTX-A
Experimental: Placebo/Saline
Saline intralesional injection
Other: Placebo
Given as an intralesional injection

Detailed Description:

Background:

  • Cutaneous leiomyomas are smooth muscle tumors that may arise sporadically or in association with an inherited cancer-related genodermatosis.
  • Leiomyomas may be severely painful, and current management is generally unsatisfactory.
  • Studies demonstrate increased nerve density within and around leiomyomas as well as increased acetylcholinesterase staining of associated nerves.
  • Botulinum toxin-A has been used in the treatment of pain syndromes.
  • Based on the known mechanisms of action of botulinum toxin-A, treatment with botulinum toxin-A (BOTOX; Allergan, Inc.), may ameliorate the severe paroxysmal pain of symptomatic cutaneous leiomyomas.

Objectives:

  • Primary: To assess change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls.
  • Primary: To assess improvement in pain based on Visual Analog Scale (VAS) after application of ice at Week 4 compared to baseline in treated patients versus controls.
  • Secondary: To assess change in magnitude and in frequency of painful episodes based on a weekly patient diary in treated patients versus controls.
  • Secondary: To assess persistence of pain control at Weeks 12 based on the BPI and VAS.
  • Secondary: To assess the frequency of rescue pain medication use in treated patients versus controls during the 24 week study period.
  • Secondary: To determine the impact of leiomyoma treatment on quality of life.
  • Secondary: To assess change in patient s condition based on the Patient Global Impression of Change.
  • Secondary: To evaluate the immunohistochemical staining of nerve fibers and muscle in cutaneous leiomyomas in control and treated lesions following the conclusion of the study.

Eligibility:

  • Subjects greater than or equal to18 years with at least 1 symptomatic cutaneous leiomyoma.
  • Pain symptoms must occur at least once a week and be characterized as greater than or equal to 5 out of 10.

Design:

  • A 12-week double-blind placebo controlled pilot study of 18 subjects with symptomatic leiomyomas will include initial assessment with BPI, photography, and skin biopsies, followed by treatment of subjects who initially received placebo.
  • Cutaneous leiomyomas will undergo intralesional injection with botulinum toxin-A.
  • Subjects will return at Weeks 4 and 12 for repeat assessment using pain and quality of life questionnaires and photography. Skin biopsies will be performed at week 12.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

    1. Subjects must be age greater than or equal to18 years.
    2. Subjects must have a prior biopsy-proven diagnosis of cutaneous leiomyoma.
    3. Subjects must have at least 1 symptomatic leiomyomas or regions less than or equal to 60 cm^2 of leiomyomas with pain characterized as greater than 4 based on a 10-point scale, indicating pain of at least moderate severity.
    4. Pain episodes must occur at least once a week.
    5. Subjects must have the ability to participate fully and comply with the procedures of the protocol in the opinion of the investigator.
    6. Written informed consent has been obtained including consenting to have tissue samples stored, however subjects are allowed to refuse sample storage.
    7. Negative urine or serum pregnancy test in females of childbearing potential.
    8. Subjects who are clinically stable such that they can be expected to complete the 24-week study.

EXCLUSION CRITERIA:

  1. Subjects with allergies to BTX-A.
  2. Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
  3. Subjects with neuromuscular junction disorders (ie. myasthenia gravis or Lambert-Eaton syndrome) or peripheral motor neuropathic diseases (ie. amyotrophic lateral sclerosis or motor neuropathy).
  4. Subjects with infection at the intended sites of injection.
  5. Subjects who have had prior Botulinum toxin product within the past 6 months.
  6. Subjects with pain resulting from other disease(s), specifically:

    • pain that requires intermittent or ongoing treatment with narcotics
    • severe, debilitating, or acute pain originating from sources other than leiomyomas
  7. Subjects taking pain medications, neuroactive agents, or other therapy directed toward treatment of cutaneous leiomyomas concurrently or within 5 days or 5 half-lives (whichever is longer) of BTX-A treatment, other than specified rescue pain medications). Patients currently on therapy directed toward OTHER mild to moderate chronic pain will be evaluated on a case-by-case basis for inclusion. Patients with well-controlled mild to moderate chronic pain such as that associated with osteoarthritis, who do not require narcotic therapy, will NOT be excluded. Aspirin for pain relief or for other indications is also acceptable.
  8. Subjects with late-stage cancers or unstable disease (such as hemodynamic instability, i.e., systolic or diastolic blood pressure fall of 20 mm Hg or greater from the stable patient s baseline measurement).
  9. A condition or situation that, in the investigator's opinion, may put the subject at significant risk or interfere significantly with the subject's participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00971620

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Edward W Cowen, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
Publications:
Responsible Party: Edward Cowen, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00971620     History of Changes
Obsolete Identifiers: NCT00842725
Other Study ID Numbers: 090072
09-C-0072
Study First Received: September 3, 2009
Results First Received: December 11, 2014
Last Updated: February 23, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Edward Cowen, M.D., National Institutes of Health Clinical Center (CC):
Cutaneous Leiomyomas
Skin Pain
Botox Therapy
Hereditary Leiomyomatosis
Renal Cell Cancer
Cutaneous Leiomyoma

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Leiomyoma
Myofibroma
Leiomyomatosis
Skin Neoplasms
Uterine Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Connective Tissue Diseases
Skin Diseases
Genital Neoplasms, Female
Uterine Diseases
Genital Diseases, Female
Botulinum Toxins
Botulinum Toxins, Type A
abobotulinumtoxinA
onabotulinumtoxinA
Acetylcholine Release Inhibitors

ClinicalTrials.gov processed this record on July 21, 2017